| Previous Close | 6.10 |
| Open | 6.32 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 6.32 - 6.48 |
| 52 Week Range | 5.05 - 11.29 |
| Volume | 1,790 |
| Avg. Volume | 426 |
| Market Cap | 27.13M |
| Beta | 0.49 |
| PE Ratio (TTM) | -2.27 |
| EPS (TTM) | -2.8 |
| Earnings Date | N/A |
| Dividend & Yield | 0.60 (9.93%) |
| Ex-Dividend Date | 2017-04-11 |
| 1y Target Est | N/A |
- GlobeNewswire•5 hours ago
Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
BERKELEY HEIGHTS, N.J., July 21, 2017-- Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop ...
- GlobeNewswire•2 months ago
Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results
BERKELEY HEIGHTS, N.J., May 11, 2017-- Cyclacel Pharmaceuticals, Inc. a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
- GlobeNewswire•3 months ago
Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
BERKELEY HEIGHTS, N.J., May 05, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
